Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine/threonine-protein kinase Chk2 (CHEK2) is a multifunctional enzyme and a key component of the DNA damage response (DDR). It acts as a tumor suppressor and plays central roles in cell cycle checkpoint control, DNA repair, apoptosis, and maintenance of genomic stability. CHEK2 is activated primarily in response to DNA double-strand breaks and subsequently phosphorylates various downstream targets involved in cell cycle regulation, DNA repair, and apoptosis. Mutations in CHEK2 are associated with increased cancer susceptibility, making it an attractive target for cancer therapy research.
CHK2 inhibitors (in development) aim to disrupt its kinase activity, leading to cell cycle arrest or apoptosis in cancer cells with compromised DNA damage response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine/threonine-protein kinase Chk2 (CHEK2).